priors.science/reviews/targeted-therapy-prostate-cancer

Targeted Therapy Prostate Cancer

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

17claims tracked
238primary papers reviewed
26 Oct 2026latest evidence review
11 Established · 4 Likely · 1 Uncertain · 0 Doubtful · 1 Refuted  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Abiraterone overall survival benefit in metastatic hormone-sensitive prostate cancerAdt IntensifyEstablished95%18
Enzalutamide overall survival benefit in metastatic castration-resistant prostate cancerArpiEstablished93%14
Abiraterone overall survival benefit post-docetaxel in metastatic castration-resistant prostate cancerArpiEstablished92%19
Enzalutamide metastasis-free survival benefit in non-metastatic castration-resistant prostate cancerNmcrpcEstablished91%15thin basis
Overall survival benefit of androgen receptor inhibitors in non-metastatic castration-resistant prostate cancerNmcrpcEstablished90%16
Olaparib radiographic progression-free survival in homologous recombination repair-mutant metastatic castration-resistant prostate cancerPARPEstablished88%15
Lu-PSMA-617 overall survival in metastatic castration-resistant prostate cancer (VISION)PsmaEstablished88%18
Radium-223 overall survival in bone-only metastatic castration-resistant prostate cancerBoneEstablished87%18
PARP plus androgen receptor inhibitor combination in metastatic castration-resistant prostate cancerPARPEstablished87%13
Androgen receptor splice variant 7 predicts androgen receptor inhibitor resistanceResistanceEstablished87%16
Androgen receptor inhibitor sequence cross-resistanceArpiLong-standingLikely80%19
PSMA PET staging superior to conventional imagingPsmaLong-standingLikely74%17
PTEN loss and androgen receptor inhibitor resistance in metastatic castration-resistant prostate cancerResistanceLikely73%17
Pembrolizumab activity in microsatellite instability-high or high tumour mutational burden prostate cancerResistanceLikely70%15
Enzalutamide or darolutamide overall survival in metastatic hormone-sensitive prostate cancerAdt IntensifyUncertain68%21
Rucaparib benefit in non-BRCA homologous recombination repair metastatic castration-resistant prostate cancerPARPRefuted15%18
Track Targeted Therapy Prostate Cancer.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.